Abiomed, Inc. (ABMD)

NASDAQ: ABMD · IEX Real-Time Price · USD
290.93
-2.41 (-0.82%)
At close: Aug 11, 2022 4:00 PM
290.45
-0.48 (-0.16%)
After-hours: Aug 11, 2022 5:38 PM EDT
-0.82%
Market Cap 13.23B
Revenue (ttm) 1.06B
Net Income (ttm) 217.58M
Shares Out 45.46M
EPS (ttm) 4.96
PE Ratio 58.66
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 184,955
Open 295.85
Previous Close 293.34
Day's Range 289.54 - 301.49
52-Week Range 219.85 - 379.30
Beta 1.35
Analysts Buy
Price Target 332.35 (+14.2%)
Earnings Date Aug 4, 2022

About ABMD

Abiomed, Inc. engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides a continuum of care to heart failure patients. The company offers Impella 2.5, a percutaneous micro heart pump with integrated motor and sensors; and Impella CP, a device for use by interventional cardiologists to support patients in the cath lab, as well as by cardiac surgeons in the heart surgery suite. It also provides Impella 5.0, Impella LD, and Impella 5.5, which are percutaneous ... [Read more...]

Industry Health Care Equipment & Supplies
IPO Date Jul 29, 1987
CEO Michael Minogue
Employees 2,003
Stock Exchange NASDAQ
Ticker Symbol ABMD
Full Company Profile

Financial Performance

In 2021, Abiomed's revenue was $1.03 billion, an increase of 21.74% compared to the previous year's $847.52 million. Earnings were $136.51 million, a decrease of -39.47%.

Financial Statements

Analyst Forecast

According to 15 analysts, the average rating for ABMD stock is "Buy." The 12-month stock price forecast is 332.35, which is an increase of 14.24% from the latest price.

Price Target
$332.35
(14.24% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Why Shares of Abiomed Rose 18.4% in July

The company's stock rose steadily throughout the month.

Abiomed (ABMD) Q1 Earnings Top Estimates, Margins Down

Abiomed's (ABMD) strength in Impella product revenues drives its Q1 top line.

Abiomed (ABMD) Q1 Earnings Top Estimates

Abiomed (ABMD) delivered earnings and revenue surprises of 15.74% and 0.42%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

ABIOMED Announces First Quarter Record Revenue of $277 Million, up 10% Year Over Year, up 12% in Constant Currency*

DANVERS, Mass.--(BUSINESS WIRE)--Abiomed announces first quarter record revenue of $277 million, up 10% year over year, up 12% in constant currency.

Abiomed (ABMD) Expected to Beat Earnings Estimates: Should You Buy?

Abiomed (ABMD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Can Abiomed (ABMD) Keep the Earnings Surprise Streak Alive?

Abiomed (ABMD) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

2 Medical Device Stocks With Extremely High GF Scores

The GF Score system from GuruFocus is a unique metric that takes into account a company's financial strength, profitability, growth, valuation and momentum to determine if the stock is likely to outperf...

Other symbols: EW

Abiomed First Quarter Fiscal 2023 Earnings and Conference Call Notification

DANVERS, Mass.--(BUSINESS WIRE)--Abiomed to release financials and host conference call to discuss the results for the first quarter of the fiscal year 2023 on August 4, 2022.

Here's Why You Should Hold on to Abiomed (ABMD) Stock For Now

Investors remain optimistic about Abiomed (ABMD) due to strength in its Impella product line.

Abiomed to Host Investor Call on Heart Failure Opportunity With Impella 5.5 and Impella BTR Heart Pumps

DANVERS, Mass.--(BUSINESS WIRE)--Abiomed to host investor call on heart failure opportunity with Impella 5.5 and Impella BTR heart pumps.

Abiomed to Present (Live) at the William Blair 42nd Annual Growth Stock Conference

DANVERS, Mass.--(BUSINESS WIRE)--Abiomed to present (live) at the William Blair 42nd Annual Growth Stock Conference.

SCAI 2022 Scientific Sessions Highlight Impella Research, Advancements to Improve Cardiogenic Shock Outcomes

DANVERS, Mass.--(BUSINESS WIRE)--Abiomed will feature the most recent Impella research, technological advances aimed at improving AMICS patient outcomes at SCAI Scientific Sessions.

Reasons to Retain Abiomed (ABMD) Stock in Your Portfolio For Now

Investors remain optimistic about Abiomed (ABMD) due to strength in its Impella product line.

Why Abiomed (ABMD) is a Top Growth Stock for the Long-Term

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Abiomed (ABMD) Q4 Earnings and Revenues Surpass Estimates

Abiomed's (ABMD) strength in Impella product revenues drives its Q4 top line.

Abiomed Announces Fourth Quarter Record Revenue of $270 Million, up 12% Year Over Year

DANVERS, Mass.--(BUSINESS WIRE)--Abiomed announces fourth quarter record revenue of $270 million, up 12% year over year.

World's First Patient Implanted with Impella BTR Minimally Invasive Heart Pump

DANVERS, Mass.--(BUSINESS WIRE)--Abiomed (Nasdaq: ABMD) announces the first patient in the world has been successfully implanted with Impella Bridge-to-Recovery (BTR).

NACD New England Honors Boston Scientific, A.D. Makepeace, Rapid7 CEO Corey Thomas, Bennie Wiley, and Jack F.

BOSTON--(BUSINESS WIRE)---- $ABMD #NACD--Corporate governance award: NACD New England honors Boston Scientific, A.D. Makepeace, Rapid7 CEO Corey Thomas, Bennie Wiley, Jack F. O'Brien on May 4

3 Medical Instruments Stocks to Buy Despite Industry Headwinds

The Zacks Medical - Instruments industry is growing on R&D investments. ALC, STE and ABMD are set to gain the most.

Other symbols: ALCSTE

Abiomed (ABMD) Announces Successful Usage of Impella in Japan

Continued adoption of Abiomed's (ABMD) Impella 5.5 with SmartAssist is likely to provide a minimally invasive surgical option for acute heart failure patients.

Abiomed Fourth Quarter Fiscal 2022 Earnings and Conference Call Notification

DANVERS, Mass.--(BUSINESS WIRE)--Abiomed announces that on Thursday, April 28, 2022, the Company will release financial results for the fourth quarter of the fiscal year 2022.

First Patient in Japan Treated with Impella 5.5 with SmartAssist

DANVERS, Mass.--(BUSINESS WIRE)--The first patient in Japan has been treated with Abiomed's Impella 5.5 with SmartAssist and the number of patients treated globally surpasses 5,000.

7 Medical Device Stocks to Buy as Covid-19 Fears Fade

With concerns about Covid-19 fading into the rearview mirror, the normalization of healthcare could benefit these medical device stocks. The post 7 Medical Device Stocks to Buy as Covid-19 Fears Fade ap...

Other symbols: EWISRGMDTSYKTMO

Abiomed CEO discusses company growth and combining products with supportive technology

The "Mad Money" host spoke with Abiomed CEO Mike Minogue on Monday's episode of the show.

Abiomed to Host Investor Call on Impella ECP, the World's Smallest Heart Pump at 9 French

DANVERS, Mass.--(BUSINESS WIRE)--Abiomed to host investor call on Impella ECP, the world's smallest heart pump at 9 french.